Magnesium and Drugs Commonly Used in Chronic Kidney Disease

William, Jeffrey H.; Richards, Katelyn R.; Danziger, John

doi:10.1053/j.ackd.2018.01.005

Cited by 16 publications

(9 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 Long-term administration of Mg-losing diuretics and Mg-containing agents under impaired Mg homeostasis leads to hypomagnesemia and hypermagnesemia, respectively. 3 Hypermagnesemia in older adults is caused mainly by the long-term administration of Mg-containing laxatives. Yamaguchi et al reported a case series of hypermagnesemia induced by Mg oxide, and speculated that hypermagnesemia occurs more frequently than previously reported.…”

Section: Dear Editormentioning

confidence: 99%

“…As the adverse outcomes of atrial fibrillation (AF) increase with age and comorbidities, 1 and AF is highly associated with frailty, 2 the association of frailty and AF outcomes is a major concern. Previous studies mostly from Western countries, including a systematic review 2 and a subanalysis of clinical trial, 3 showed conflicting results on the association of frailty and AF outcomes. Recently, we reported that frailty was associated with cardiovascular and allcause death, net clinical outcomes (a composite of stroke/systemic embolic events, major bleeding and all-cause death), and major bleeding, but not stroke or intracranial hemorrhage in a 3000-patient subcohort of the All Nippon AF In the Elderly (ANAFIE) Registry, a nationwide registry with older Japanese adults with non-valvular AF.…”

Section: Disclosure Statementmentioning

confidence: 99%

“…1 , 2 Long‐term administration of Mg‐losing diuretics and Mg‐containing agents under impaired Mg homeostasis leads to hypomagnesemia and hypermagnesemia, respectively. 3 Hypermagnesemia in older adults is caused mainly by the long‐term administration of Mg‐containing laxatives. Yamaguchi et al .…”

Section: Tablementioning

confidence: 99%

See 2 more Smart Citations

A senile case of heart failure associated with hypermagnesemia induced by magnesium‐containing laxative agent

Eiraku

Uozumi

Hieda

et al. 2022

Geriatrics Gerontology Int

View full text Add to dashboard Cite

show abstract

Section: Dear Editormentioning

confidence: 99%

Section: Disclosure Statementmentioning

confidence: 99%

See 1 more Smart Citation

A senile case of heart failure associated with hypermagnesemia induced by magnesium‐containing laxative agent

Eiraku

Uozumi

Hieda

et al. 2022

Geriatrics Gerontology Int

View full text Add to dashboard Cite

show abstract

“…In patients with CKD, the loss of renal function is counteracted by compensatory mechanisms, which maintain the serum levels of magnesium in the normal range or may even cause hypermagnesemia when renal excretion is further decreased [ 64 ]. On the other hand, some drugs commonly used by CKD patients can decrease gastrointestinal absorption of magnesium, potentially contributing to hypomagnesemia [ 65 ]. Therefore, several factors (such as the medical status, CKD stage, and drug administration) should be considered when an oral supplementation of magnesium is suggested to CKD patients.…”

Section: Nutraceuticals For Cardiovascular Calcificationmentioning

confidence: 99%

The Emerging Role of Nutraceuticals in Cardiovascular Calcification: Evidence from Preclinical and Clinical Studies

et al. 2021

View full text Add to dashboard Cite

Cardiovascular calcification is the ectopic deposition of calcium-phosphate crystals within the arterial wall and the aortic valve leaflets. This pathological process leads to increased vascular stiffness, reduced arterial elasticity, and aortic valve stenosis, increasing the risk of cardiovascular diseases. Although cardiovascular calcification is an increasing health care burden, to date no medical therapies have been approved for treating or preventing it. Considering the current lack of therapeutic strategies and the increasing prevalence of cardiovascular calcification, the investigation of some nutraceuticals to prevent this pathological condition has become prevalent in recent years. Recent preclinical and clinical studies evaluated the potential anti-calcific role of nutraceuticals (including magnesium, zinc, iron, vitamin K, and phytate) in the progression of vascular calcification, providing evidence for their dietary supplementation, especially in high-risk populations. The present review summarizes the current knowledge and latest advances for nutraceuticals with the most relevant preclinical and clinical data, including magnesium, zinc, iron, vitamin K, and phytate. Their supplementation might be recommended as a cost-effective strategy to avoid nutritional deficiency and to prevent or treat cardiovascular calcification. However, the optimal dose of nutraceuticals has not been identified and large interventional trials are warranted to support their protective effects on cardiovascular disease.

show abstract

“…In CKD, blood Mg 2+ concentrations are further affected by the use of medication (e.g. proton pump inhibitors, thiazides and loop diuretics), the prescription of diets low in potassium (food products rich in potassium are generally also rich in Mg 2+ ) and the presence of diabetes [ 47 ]. Monitoring and adjusting the blood Mg 2+ concentration in CKD patients might be relevant, as hypomagnesaemia is associated with progression to end-stage renal disease in diabetic nephropathy patients [ 48 , 49 ].…”

Section: Vascular Calcification In Ckd and The Role Of Magnesium: Obs...mentioning

confidence: 99%

Magnesium to prevent kidney disease–associated vascular calcification: crystal clear?

Braake

Vervloet

Baaij

et al. 2020

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

Vascular calcification is a prognostic marker for cardiovascular mortality in chronic kidney disease (CKD) patients. In these patients, magnesium balance is disturbed, mainly due to limited ultrafiltration of this mineral, changes in dietary intake and the use of diuretics. Observational studies in dialysis patients report that a higher blood magnesium concentration is associated with reduced risk to develop vascular calcification. Magnesium prevents osteogenic vascular smooth muscle cell transdifferentiation in in vitro and in vivo models. In addition, recent studies show that magnesium prevents calciprotein particle maturation, which may be the mechanism underlying the anti-calcification properties of magnesium. Magnesium is an essential protective factor in the calcification milieu, which helps to restore the mineral-buffering system that is overwhelmed by phosphate in CKD patients. The recognition that magnesium is a modifier of calciprotein particle maturation and mineralization of the extracellular matrix renders it a promising novel clinical tool to treat vascular calcification in CKD. Consequently, the optimal serum magnesium concentration for patients with CKD may be higher than in the general population.

show abstract

Magnesium and Drugs Commonly Used in Chronic Kidney Disease

Cited by 16 publications

References 70 publications

A senile case of heart failure associated with hypermagnesemia induced by magnesium‐containing laxative agent

A senile case of heart failure associated with hypermagnesemia induced by magnesium‐containing laxative agent

The Emerging Role of Nutraceuticals in Cardiovascular Calcification: Evidence from Preclinical and Clinical Studies

Magnesium to prevent kidney disease–associated vascular calcification: crystal clear?

Contact Info

Product

Resources

About